Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00221026
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : October 19, 2016
ICON plc
Information provided by (Responsible Party):

Brief Summary:
his study will explore the safety and activity of ECP treatment with UVADEX in inducing a clinical response (i.e., a CDAI decrease greater than or equal to 100 from baseline and/or a CDAI < 150) over a 12-week period in moderately active Crohn's disease (CDAI greater than or equal to 220 to < 450) patients who are refractory or intolerant to immunosuppressants and/or anti-TNF agents. This study will also assess response to continued treatment during a 12-week Extension Period in patients who have a clinical response at Week 12 of the Treatment Period and elect to participate in the Extension Period.

Condition or disease Intervention/treatment Phase
Crohn's Disease Drug: Methoxsalen +ECP Procedure: Extracorporeal Photopheresis Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents
Study Start Date : December 2004
Actual Primary Completion Date : June 2006
Actual Study Completion Date : June 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease
Drug Information available for: Methoxsalen

Arm Intervention/treatment
Experimental: drug
ECP + Uvadex given for 12 weeks.
Drug: Methoxsalen +ECP
ECP + Uvadex given at weeks 1-12 weeks.
Other Name: Uvadex

Procedure: Extracorporeal Photopheresis
ECP given at weeks 1 through 12.
Other Name: uvadex+ECP

Primary Outcome Measures :
  1. Crohns Disease Activity Index [ Time Frame: 12 weeks ]
    The CDAI is a questionaire giving the change of disease acitvity.This study wil llook or a decrease in CDAI score of at least 100.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed and dated informed consent must be obtained prior to conducting any study procedure.
  • Patients must be greater than or equal to 18 years of age.
  • Patients must have a body weight greater than or equal to 40 kg (88 lb).
  • Patients must have had Crohn's disease for at least 6 months duration (with colitis, ileitis, or ileocolitis) confirmed by radiography or endoscopy.
  • Patients must have a CDAI greater than or equal to 220 to < 450.
  • Patients must have a CRP concentration > 10.0 mg/L (1.0 mg/dL) or evidence of active inflammatory luminal Crohn's disease as demonstrated by superficial and/or deep ulcerations, pseudopolyps, and/or ulcerated stenosis on colonoscopy within 8 weeks of screening.
  • Patients who are receiving corticosteroids must be on a prednisone equivalent dose less than or equal to 25 mg/day or an oral (PO) budesonide dose less than or equal to 9 mg/day.
  • Patients who are receiving any of the following concomitant Crohn's disease medications must have been on a stable dose of these medications for the specified period of time PRIOR TO confirmation of eligibility (this time period may include screening): aminosalicylates, antibiotics, and immunosuppressants (i.e., 6 MP, MTX, or AZA) for at least 4 weeks; corticosteroids or PO budesonide for at least 2 weeks; anti-TNF agents (i.e., infliximab or adalimumab) for at least 8 weeks.
  • Patients who have failed treatment with immunosuppressants and/or anti-TNF agents.
  • Patients who have fistulae are permitted, provided: patients have predominantly luminal Crohn's disease, and fistulae are not associated with abscess formation.
  • Patients must have a platelet count greater than or equal to 50,000/microL (50.0 x 109/L).
  • Female patients must be: postmenopausal, surgically incapable of bearing children, or practicing an acceptable method of birth control (acceptable methods include hormonal contraceptives, intrauterine device, and spermicide and barrier). Abstinence or partner/spouse sterility may also qualify at the Investigator's discretion. If a female patient is of childbearing potential, she must have a negative urine pregnancy test at screening. Male patients must also commit to using adequate contraceptive precautions (condoms). All patients (both males and females of childbearing potential) must commit to using adequate contraceptive precautions throughout their participation in the study and for at least 3 months following their last ECP treatment
  • Patients must be able and willing to comply with all study procedures.

Exclusion Criteria:

  • Patients who are concomitantly using biologic agents other than anti-TNF agents; cyclosporine (CSA), tacrolimus (FK506), mycophenolate mofetil (MMF), or investigational Crohn's disease therapies.
  • Patients who, in the opinion of the Investigator, may not be able to remain on a stable dose of a concomitant Crohn's disease medication during the 12-week Treatment Period.
  • Patients with currently symptomatic untreated diarrhea, due to conditions other than inflammatory Crohn's disease (e.g., bacterial or parasitic gastroenteritis, bile salt diarrhea, or bacterial overgrowth).
  • Patients with symptomatic intestinal strictures.
  • Patients with stomas.
  • Patients with other local manifestations of Crohn's disease such as abscesses, or other disease manifestations for which surgery might be indicated, or which might preclude utilization of a CDAI to assess response to therapy (such as "short gut" syndrome).
  • Patients who are unable to tolerate the extracorporeal volume shifts associated with ECP treatment due to the presence of any of the following conditions: uncompensated congestive heart failure, pulmonary edema, severe chronic obstructive pulmonary disease, severe asthma, renal failure, or hepatic failure.
  • Patients receiving total parenteral nutrition, as the sole source of nutrition, within 3 weeks of screening.
  • Female patients whose hemoglobin (Hgb) is < 8.5 g/dL or male patients whose Hgb is < 10.0 g/dL at screening.
  • Patients with a poor tolerability of venipuncture or a lack of adequate venous access for required treatments and blood sampling.
  • Patients who have a known hypersensitivity or allergy to psoralen (methoxsalen).
  • Patients who have a known hypersensitivity or allergy to both heparin and citrate products.
  • Female patients who are pregnant and/or lactating.
  • Patients who have been enrolled in any investigational study for the treatment of Crohn's disease within 4 weeks of enrollment for non biologic therapies and within 8 weeks of enrollment for biologic therapies.
  • Patients who have any of the following: a co-existing melanoma, squamous cell skin carcinoma, aphakia, photosensitive disease (e.g., porphyria, systemic lupus erythematosus, or albinism), a white blood cell count > 25,000 mm3, a previous splenectomy, or a clinically significant coagulation disorder.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00221026

United States, Maryland
Bethesda, Maryland, United States
Metropolitian Gastroenterology Group
Chevy Chase, Maryland, United States
United States, New Jersey
Morristown Memorial Hospital
Morristown, New Jersey, United States
United States, New York
Mount Sinai Medical Center
New York, New York, United States
General Hospital of Vienna
Vienna, Austria
Hospital Erasme/ULB
Brussels, Belgium
UZ Leuven
Leuven, Belgium
Universitat St Josef
Bochum, Germany
Krankenhaus Duren gem.GmbH
Duren, Germany
Universitatsklinik Essen
Essen, Germany
Jena, Germany
Universitatsklinikum Mannheim
Mannheim, Germany
University Hospital Munich-Grosshadem
Munich, Germany
Klinikum Oldenberg
Oldenburg, Germany
Medizinische Universitatsklinik Ulm
Ulm, Germany
Sponsors and Collaborators
ICON plc

Responsible Party: Mallinckrodt Identifier: NCT00221026     History of Changes
Obsolete Identifiers: NCT00105261
Other Study ID Numbers: CD-2
First Posted: September 22, 2005    Key Record Dates
Last Update Posted: October 19, 2016
Last Verified: October 2016

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Photosensitizing Agents
Dermatologic Agents